- Home
- MIRM vs TENB Comparison
MIRM vs TENB Comparison
Compare MIRM & TENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- TENB
- Stock Information
- Founded
- MIRM 2018
- TENB 2002
- Country
- MIRM United States
- TENB United States
- Employees
- MIRM 349
- TENB N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- TENB Computer Software: Prepackaged Software
- Sector
- MIRM Health Care
- TENB Technology
- Exchange
- MIRM Nasdaq
- TENB Nasdaq
- Market Cap
- MIRM 3.7B
- TENB 3.6B
- IPO Year
- MIRM 2019
- TENB 2018
- Fundamental
- Price
- MIRM $72.85
- TENB $29.90
- Analyst Decision
- MIRM Strong Buy
- TENB Buy
- Analyst Count
- MIRM 11
- TENB 17
- Target Price
- MIRM $76.09
- TENB $41.06
- AVG Volume (30 Days)
- MIRM 712.9K
- TENB 1.3M
- Earning Date
- MIRM 11-11-2025
- TENB 10-29-2025
- Dividend Yield
- MIRM N/A
- TENB N/A
- EPS Growth
- MIRM N/A
- TENB N/A
- EPS
- MIRM N/A
- TENB N/A
- Revenue
- MIRM $429,161,000.00
- TENB $949,251,000.00
- Revenue This Year
- MIRM $53.14
- TENB $11.66
- Revenue Next Year
- MIRM $19.83
- TENB $7.86
- P/E Ratio
- MIRM N/A
- TENB N/A
- Revenue Growth
- MIRM 62.33
- TENB 11.41
- 52 Week Low
- MIRM $36.88
- TENB $28.51
- 52 Week High
- MIRM $78.10
- TENB $45.45
- Technical
- Relative Strength Index (RSI)
- MIRM 56.46
- TENB 44.21
- Support Level
- MIRM $70.49
- TENB $28.97
- Resistance Level
- MIRM $74.96
- TENB $30.03
- Average True Range (ATR)
- MIRM 1.82
- TENB 0.71
- MACD
- MIRM -0.72
- TENB -0.01
- Stochastic Oscillator
- MIRM 51.03
- TENB 28.01
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.